Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Ruxolitinib cream provides relief for atopic dermatitis

30 May 2020

Ruxolitinib (RUX) creams appear to ease itch severity and improve quality of life (QoL) among patients with atopic dermatitis (AD), a new study has found.

Researchers randomly assigned 307 (median age, 35.0 years; 54.7 percent female) adult AD patients to receive 8 weeks of RUX, triamcinolone or vehicle creams. RUX was given in four doses: 1.5% twice-daily (BID), and 1.5%, 0.5%, 0.15% all once-daily (QD). Both passive and active controls were given BID. Itch, the primary study outcome, was measured using the numerical rating scale (NRS), while QoL was assessed using Skindex-16.

RUX cream 1.5% BID significantly reduced NRS itch scores within 36 hours relative to the vehicle comparator (–1.8 vs 0.2; p<0.0001).

Moreover, all RUX cream treatments led to reductions in itch NRS scores within the first 2 weeks of treatment, with effects persisting for the rest of the trial period. After 4 weeks of treatment, both BID (–64.6) and QD (–54.0) regimens of the 1.5% RUX cream yielded better itch relief than triamcinolone (–50.3). However, only the BID RUX regimen was statistically superior (p=0.003).

These symptomatic improvements coincided with better QoL. All RUX cream arms showed significant improvements relative to baseline. This was particularly true in the 1.5% BID regimen, where Skindex-16 scores improved by a mean of 63.5 percent and 73.2 percent at weeks 2 and 8, respectively. In comparison, vehicle participants only saw QoL improvements of 10.5-percent and 19.7-percent at these corresponding timepoints.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.